Evaluation of the Side Effects of Antiretroviral Treatment

Evaluation of the Side Effects of Antiretroviral Treatment

Introduction: The frequency of antiretroviral therapy (ART)-induced side effects varies in HIV-infected patients. In this study, we aimed to compare drug-induced side effects developing in patients receiving different ART regimens. Materials and Methods: This study was performed after obtaining app...

Full description

Bibliographic Details
Main Authors:	Sedef BAŞGÖNÜL, Serap GENÇER, Serdar ÖZER
Format:	Article
Language:	Turkish
Published:	Galenos Yayinevi 2018-12-01
Series:	Mediterranean Journal of Infection, Microbes and Antimicrobials
Subjects:	HIV antiretroviral therapy tenofovir dolutegravir darunavir
Online Access:	http://mjima.org/text.php?&id=116

Similar Items

Low plasmatic concentration of intensified antiretroviral therapy in a pregnant woman: a case report
by: Sheila Chiesi, et al.
Published: (2019-07-01)

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
by: Tony Antoniou, et al.
Published: (2017-04-01)

Dolutegravir/rilpivirine for the treatment of HIV-1 infection
by: Dowers E, et al.
Published: (2018-11-01)

A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data
by: Amedeo F. Capetti, et al.
Published: (2017-09-01)

Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance
by: Eva Wolf, et al.
Published: (2021-09-01)

Mild self-declared side effects of boosted darunavir associated with other antiretrovirals in Romanian HIV-1 infected patients
by: Ruxandra C. MARIN, et al.
Published: (2021-09-01)

Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy
by: Kairoonisha Mahomed, et al.
Published: (2020-07-01)

HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study
by: Marianne Harris, et al.
Published: (2017-11-01)

Long-term weight gain after initiating combination antiretroviral therapy in treatment-naïve Asian people living with human immunodeficiency virus
by: Naokatsu Ando, et al.
Published: (2021-09-01)

Darunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era
by: Squillace N, et al.
Published: (2018-10-01)

Reconsidering first-line antiretroviral therapy in the pregnant population
by: Yoo, Sunny
Published: (2016)

Are new antiretroviral treatments increasing the risks of clinical obesity?
by: Andrew Hill, et al.
Published: (2019-01-01)

Comparison of Tolerability and Impact on Metabolic Profiles of Antiretroviral Regimens Containing Darunavir/Ritonavir or Darunavir/Cobicistat in Romanian HIV Infected Patients
by: Ruxandra-Cristina Marin, et al.
Published: (2021-08-01)

Renal function in Ethiopian HIV-positive adults on antiretroviral treatment with and without tenofovir
by: Daniel Yilma, et al.
Published: (2020-08-01)

Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study
by: Inés Suárez-García, et al.
Published: (2020-07-01)

Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
by: Zamora FJ, et al.
Published: (2019-10-01)

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice
by: Alberto Borghetti, et al.
Published: (2019-01-01)

Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter
by: Darren eMoss, et al.
Published: (2015-04-01)

The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study
by: Calcagno, A., et al.
Published: (2022)

Development and validation of stability-indicating HPLC method for simeltaneous determination of Lamivudine, Tenofovir, and Dolutegravir in bulk and their tablet dosage form
by: Nagasarapu Mallikarjuna Rao, et al.
Published: (2015-12-01)

Treatment with Commonly Used Antiretroviral Drugs Induces a Type I/III Interferon Signature in the Gut in the Absence of HIV Infection
by: Sean M. Hughes, et al.
Published: (2020-09-01)

Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort
by: Chua Arlene C, et al.
Published: (2012-06-01)

Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS
by: Navarro J, et al.
Published: (2016-10-01)

High rates of transmitted NNRTI resistance among persons with acute HIV infection in Malawi: implications for first-line dolutegravir scale-up
by: Sarah E. Rutstein, et al.
Published: (2019-02-01)

Will Drug Resistance against Dolutegravir in Initial Therapy Ever Occur?
by: Mark eWainberg, et al.
Published: (2015-04-01)

Efficacy and safety of darunavir and etravirine in a patient with retroviruses and multiple virologic failure
by: Claudia Bernardini, et al.
Published: (2009-09-01)

High rate of virologic suppression with darunavir/ritonavir plus optimized background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil
by: José Ernesto Vidal, et al.
Published: (2013-02-01)

High rate of virologic suppression with darunavir/ritonavir plus optimized background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil
by: José Ernesto Vidal, et al.

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
by: Ruxandra-Cristina Marin, et al.
Published: (2021-03-01)

Factors associated to modification of first-line antiretroviral therapy due to adverse events in people living with HIV/AIDS
by: Larissa Negromonte Azevedo, et al.
Published: (2020-01-01)

Changing trends in lipid profile and biomarkers of renal function and bone metabolism before and after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study
by: Mahoko Ikeda, et al.
Published: (2021-05-01)

Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis
by: Sonya J. Snedecor, et al.
Published: (2019-05-01)

Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis
by: Katharina Nickel, et al.
Published: (2021-02-01)

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study
by: Gregory D. Huhn, et al.
Published: (2019-08-01)

Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection
by: Crutchley RD, et al.
Published: (2016-03-01)

The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV
by: Laura Waters, et al.
Published: (2021-03-01)

Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal
by: Van Rompay Koen K A, et al.
Published: (2012-07-01)

Modern antiretroviral regimens
by: A. V. Kravchenko
Published: (2016-12-01)

Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort
by: Bernard Surial, et al.
Published: (2019-10-01)

Circulating sclerostin is associated with bone mineral density independent of HIV-serostatus
by: Ryan D. Ross, et al.
Published: (2020-06-01)